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Summary.-In a Phase I study, melphalan 140 mg/M2 was administered to 8 patients
with disseminated malignant melanoma. Marrow was removed from the patients
immediately before melphalan administration and returned i.v. 8 h later. Studies on
marrow culture and melphalan pharmacokinetics predicted that this was a safe time
to administer non-cryopreserved marrow. Four patients received lower doses of
i.v. melphalan without autologous marrow. In the group receiving autologous marrow
the time for recovery of peripheral-blood granulocytes to 800/mm3 or greater was
significantly less (P=0-01) than in those not receiving marrow. In 7 patients the
tumour showed evidence of response to the drug and there was 1 complete remission.
This treatment deserves investigation in patients with tumours more sensitive to
drugs than melanoma.
A PROBLEM in human cancer chemo-
therapy is that for some cytotoxic drugs
the safe dose is limited by damage to the
marrow, yet for compounds such as
alkylating agents an increased dose would
be expected to increase the tumour-cell
kill. Melphalan, for instance, shows a log-
linear dose-response curve against human
malignant melanoma xenografts growing
in immune-deprived mice over the dose
ranige 5-25 mg/kg (Selby, 1978, personal
comm.), reflecting the clinical experience
that, although conventional oral doses
(.10 mg on 5 days monthly) of melph-
alan produce regressions in only about
9% of melanoma patients (Luce, 1975),
the higher concentrations achieved in
isolated limb perfusions are much more
effective (Wreaver et al., 1975). Where
marrow toxicity is the dose-limiting
factor, this problem can to some extent
be overcome by the use of reverse-barrier
nursing, broad-spectrum antibiotics and
platelet concentrates to support the
patient during the period of marrow
hypoplasia, and we used this approach
in a small series of patients with far-
advanced tumours (2 with malignant
melanoma, 2 with testicular teratoma)
who were given i.v. melphalan in doses
ranging from 60 to 125 mg/Mr2. Although
2 patients (one from each group) achieved
significant tumour regressions, this regi-
men was too toxic, since white-cell counts
took nearly 4 weeks to become re-
established above 1000/mm3. However,
serious toxicity was limited to myelo-
suppression, which raised the possibility
of marrow "rescue" with non-cryopre-
served autologous marrow harvested im-
mediately before treatment.
Combining marrow autografting with
chemotherapy is not new. Attempts have
been made to do this, using cryopreserved
marrow, in Burkitt's lymphoma (Ziegler
et al., 1977) and in a wide variety of other
tumours (Westbury et al., 1959; Clifford
et al., 1961; Humble et al., 1975; TobiasMARROW AUTOTRANSPLANTS IN MELANOMA
et at., 1977). Furthermore, Ariel & Pack
(1962) treated 31 melanoma patients with
100 mg i.v. melphalan plus non-cryo-
preserved autologous bone marrow and
noted objective responses in li of the
tumours, although unfortunately the
haematological effect ofthe marrow trans-
fusion was not clearly documented.
In Ziegler's study with Burkitt's lymph-
oma the results were encouraging, but it
would be fair to say that in most other
studies the results have been equivocal,
both from the standpoint ofdemonstrating
that autologous marrow infusion acceler-
ates marrow recovery from drug damage
and from that of showing that higher
doses of drug produce a significantly
greater antitumour effect. However, the
impression remains that the autografts
were of some value, and the antitumour
effects were sometimes greater than ex-
pected.
There are considerable practical prob-
lems in the cryopreservation of large
voltumes of marrow, and Tobias et al.
(1977) found very variable stem cell
viabilities at the time of reinfusion of
marrow preserved in this way. We have
therefore approached this problem with 2
main aims first to choose a drug which
has such a short life in the patient that
cryopreservation of the marrow is un-
necessary, so that the whole procedure-
marrow harvest, drug administration and
return of marrow to the patient can be
accomplished in a few hours and, second,
to establish unequivocally whether or not
nmarrow autotransplantation aids marrow
recovery. Because of the short half-life of
i.v. melphalan it seemed possible that the
whole procedure of marrow harvest, drug
administration and marrow reinfusion
could be performed on the same day with-
out recourse to cryopreservation. Patients
with advanced malignant melanoma were
chosen for the study, because conventional
doses of drugs rarely produce regression
rates greater than 20%o and complete re-
missions are very rare, so it seemed proper
to attempt more radical chemotherapy in
these patients.
In order to establish the optimal
timing for removal ofthe marrow, melpha-
lan administration, and reinfusion of the
marrow, it was necessary first to measure
melphalan levels in plasma and urine after
a single i.v. injection, since the persistence
of toxic levels of the drug at the time of
reinfusion could destroy the reimplanted
marrow. Secondly it was necessary to
measure the viability of aspirated human
marrow kept without cryopreservation.
PATIENTS ANI) METHODS (I)
Quantihfication ofmrnelphalan inurineandpla8siia
Hitlherto there have been no studies on the
levels of melphalan in body fluids after the
high doses given in the present study. How-
ever, a recently published study (Tattersall
et al., 1978) in w%Nhich conventional doses were
given (i.v. injection-20-23 mg/M2) produced
evidenice that the plasma half-life wras short
(,1 h) though there was evidence for pro-
longed persistence at low levels in a terminal
elimination phase. Likewise urinary output,
measured both in terms of excretion of radio-
activity after administration of the 14C_
labelled drug, and by mass spectrometry-
stable isotope dilution, diminished rapidly
after 2 h. The latter technique was used in
the present determinations of plasma and
urine levels of melphalan. Only the altera-
tions from the experiment procedure des-
cribed previously (Tattersall et al., 1978) are
given here.
Patient.s. All patients received a single i.v.
injection of 140 mg/M2 melphalan at Time 0.
Assay of melphalan in urine.-Six patients
were studied. Urine was collected by catheter-
ization, and samples removed at hourly
intervals and the volume determined. Samples
were stored frozen (-30°C). To an aliquot
was added the appropriate volume of a solu-
tion of melphalan-d2 (1-00 mg in 1 ml 0-1N
HCI).
Because of the sharp fall in the levels with
time, the volumes of urine taken and the
volumes of standard solution added were
appropriately varied to give convenient
ratios in the mass spectra for m/e 230:m/e
232 [M-CH(NH2)CO2CH31+ for the methyl
esters of melphalan and its d2 analogue. Thus
for the samples taken up to 4 h. 50 ,lI of
standard was added to 0 5 ml of urine, from
4 to 6 h 20 ,ul in 1 ml and subsequently 10 ,ul
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in I mnl. Crude inelphalan was recovered from
Amberlite XAD-2 resin as described pre-
viously. and was purified by thin-layer
chromatography on Silica gel (Merck Kieselgel
GF254) using chloroform methanol: water,
28:10:1-8, as developing solvent. The UV-
absorbing bands corresponding in RF value
to melphalan were removed, eluted wxith
methanol and the eluate conventionally
methylated with ethereal diazomethane.
From the mass spectrum of the resulting
mixture of the methyl esters, the ratio of
melphalan to its d2 analogue w-as determined
as previously described.
The levels are expressed in terms ofcumula-
tive excretion of drug (Fig. 1).
Assay of melphalan in plasma-.Five
patients were studied. The procedure fol-
lowed was that used for urine, except that in
all cases 10 pd of standard w,as added to 1 ml
of plasma. Blood samples w%ere collected at
5 and 30 min, and 1, 2, and 3 h. The plasma
levels are show%in in Fig. 2. Five patients had
initial (5 min) melphalan levels measured,
4 had levels measured at 30 min and 1 h, and
3 had levels measured at 2 h.
Forthecalibrationlineusingnormalplasma,
1 ml aliquots were treated with 10 pu of
standard and either 0, 1, 2, 5 or 10 ,ul of
melphalan (1.00 mg/ml). The observed ratios
for m/e 230: m/e 232 in the mass spectra
obtained after work-up were corrected (Tat-
tersall et al., 1978) mainly for recontribution
to m/e 232 from the 37CI-containing ion from
the unlabelled melphalan, and the corrected
values plotted against melphalan concentra-
tion (Fig. 3).
RESULTS AND DISCUSSION (I)
Urinary excretion ofunchanged melpha-
lan was virtually complete in 6 h (Fig. 1),
supporting the choice of this time as safe
for autologous marrow reinfusion. There
was a wide range of melphalan recovery as
a proportion of the total dose adminis-
tered. This ranged from 96% (240 mg
recovered/250 mg administered) for VA to
32% (70 mg recovered/220 mg adminis-
tered for AK. We do not know why, but
possible explanations are variation in the
degree of melphalan binding to plasma
proteins between patients or variations in
the degree of hydrolysis of the melphalan.
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Fi'{c. 1. Cumulative urinaIy excretion ofmel-
phalan after single i.v. injection of
140 mg/M2 in 6 patients.
It cannot be due to metabolism of the
drug, since this does not occur.
Plasma data (Fig. 2) were less complete.
One ,ug of melphalan was easily quantified
in 1 ml of normal plasma (Dr M. Jarman)
containing 10 /tg of d2 standard. Thus in
the mass spectrum of the mixture of
methyl obtained therefrom, the signal
intensity (see Fig. 3) for melphalan (m/e
230) was 12% of that for the d2 analogue
(m/e 232). The relative intensity for m/e
230 when no melphalan was added was
2%. Thus I ,ug/ml is in principle easily
detected and measured by the method
described here. However, some of the
plasma samples from treated patients,
particularly those taken for the later
times, failed to provide such contaminant-
free spectra, and in such cases only upper
limits could be established. In Fig. 2 the
plasma melphalan levels are expressed as
means of percentages of the 5min levels
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FIG. 2. Mean plasma melphalan levels as a
percentage of initial plasma melphalan
level after injection of 140 mg/M2 i.v.
Numbers above s.d. bars No. of patients
per point. Initial melphalan level (at
5 min)= 8-2+2-7 uog/ml (range 5 3-
11-5 ,og/ml). Broken line shows limit of
dletection.
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for each patient. The 5min levels varied
widely, with a range 5-3-115 ,ug/ml, but
in no patient could melphalan be detected
in the plasma after 2 h.
These limited data supported the con-
clusion that 6 h and after was safe for
marrow reinfusion, since plasma levels
would be sufficiently low to minimize
toxic effects on the reimplanted cells.
PATIENTS AND METHODS (II)
Marrow viability at 4°C
Colony-forming ability in vitro (CFU-C)
was used as a measure of the functional
viability of the marrow after aspiration.
Aliquots of whole marrow, in preservative-
free heparin were kept at 4°C for up to 24 h
before the assay was set up. At the time of
each assay, a sample of marrow was allowed
to sediment by gravity at room temperature,
the buffy coat removed and the cells washed
3 times. Colony formation was assayed with
leucocyte feeder layers as the sources of
colony-stimulating activity (Pike & Robinson,
1970) with the addition of lysed rat erythro-
cytes to improve colony growth (Gordon et al.,
unpub.). After 10-day incubation at 37°C in a
humidified atmosphere of 10% CO2, colonies
containing more than 50 cells were counted
under a dissecting microscope.
The results in Fig. 4 show that there was no
significant loss of colony-forming ability
when the marrow was held at 4°C for up to
10 h. Longer periods of storage led to a
gradualdecrease in marrowviabilitymeasured
in this way.
Since melphalan was undetectable in
plasma after 2 h and in urine after 6 h and
non-cryopreserved, heparinized marrow will
grow control numbers ofgranulocytic colonies
after 8 h storage at 4°C, 8 h was chosen as the
1 .0 -
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Ratio Melphalan-do: Melphalan-d2
FIG. 3. Corrected peak-height ratio m/e
230: m/e 232 plotted against melphalan
concentiration.
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FIG. 4. Granulocytic colony formation as a
function of length of time marrow is
stored at 4°C.
Uv
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time to reinfuse the marrow after melphalan
administration.
Patients.-Eight patients, details of whom
are given in Table I, were treated with 140
mg/m2 melphalan i.v. followed by a marrow
autograft. All had widely disseminated malig-
nant melanoma which was sufficiently ad-
vanced to require palliation but were other-
wise in good physical condition, and all were
under the age of 65. Patients were excluded
from the study if they had impaired renal
function, marrow infiltration, or if the bone
scan or radiological skeletal survey showed
bone involvement.
TABLE I.-Clinical details of 8 patients with malignant melanoma treated with 140 Mg/r2
melphalan i.v. and marrow autograft
Case Age Sex
1 49 M
Site of
primary
Right foot
Length of
history
3 years
Previous
treatment
Excision of
primary
Ae
do
mel[
(I
2 55 F Left leg 3 years Left inguinal
block dissection
3 35 F Left arm
4 33 M Back
5 29 M Left
conjunctiva
6 34 F Neck
7 36 F Back
17 months Left axillary
block dissection.
Adjuvant DTIC+
Vincristine
16 months Bilateral axillary
block dissections.
Adjuvant DTIC+
Vincristine. CCNU
7 years Excision of
primary
18 months Left cervical
block dissection
7 years Excision of
primary
8 35 F Right 2 years Right axillary
shoulder block dissection
ctual
ose of
)halan Pre-treatment
mg) deposits
250 Regional lymph
node distant
cutaneous and
lung
Response to
treatment
No regression.
Died after 12
months
230 Extensive Minor (<50%)
cutaneous regression skin
left leg nodules for 2
months. Died
after 8 months
210 Extensive Relief of pain
intra-abdominal with complete
disease clearing of
abdominal
ultrasonogram
for 3 months.
Died after
5 months
300 Widespread Complete
cutaneous regression of
nearly all skin
deposits for
2 months
220 Skin, lung and Minor (<50%)
liver regression of
skin and lung
deposits. Died
after 3 weeks
with extensive
intra-abdominal
disease and
E. coli
septicaemia
230 Skin, lung, >50%
extensive liver regression of
skin deposits but
concurrently
progressing liver
disease
200 Widespread >50%
skin plus lung regression of
skin and lung
deposits for
2 months
240 Massive Complete
recurrence regression of
right axilla. hepatic and
Multiple liver locally recurrent
metastases disease for
4 months
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Procedure.-Under a light general anaes-
thetic a urinary catheter and central venous
pressure line were introduced. The patients
were heparinized wiith a single dose of 1,500
u/M2 to facilitate marrowr aspiration. They
were placed supine and marrowA and blood
were aspirated from the anterior iliac crests
through heparinized Salah marrowA aspiration
needles into 20 ml sterile heparinized syringes.
After 200-300 ml of blood/marrow had been
aspirated the patients were placed face down
and the posterior iliac crests were sampled.
Finally the sternum was used as a source of
marrow. Between 2 and 4 ml of marrow was
aspirated from each site. Multiple skin punc-
tures were unnecessary, as the needles could
be moved around under the skin, and usually
only 2 skin punctures were needed on each
side. Marrow was expressed from the syringes
into a sterile plastic bag until 2-5 x 108/kg
nucleated marrow cells had been harvested
(200-500 ml of blood and marrow).
When the marrow harvest wNas complete
the mixture ofheparinized blood and marrow
was placed in a 4°C refrigerator and the
patient returned to the ward w-here 140 mg/
m2 melphalan was given i.v. The drug is
supplied with its own diluent, and was made
up immediately before injection, and it was
injected as a bolus into the side arm of a fast
running drip. (It can be very painful ifa large
vein is not used and the injection is not made
slowly).
The melphalan was followed by 20 mg
frusemide i.v. and 2 1 of fluid were given i.v.
over the next 3 h in order to prevent a high
urinary melphalan concentration. Anti-
emetics were given as required.
Hypotensive episodes occurred in the first
2 patients within 12 h of this procedure,
probably due to a combination of the anaes-
thetic and the loss of blood aspirated wAith the
marrow, and 2 units of blood were therefore
given rapidly in the theatre to subsequent
patients, w-hose pulse, blood pressure and
central venous pressure were recorded every
15 min and urine output hourly until the
marrow was returned. After the adoption
of this routine, there wtere no further hypo-
tensive episodes.
Eight hours after the melphalan had been
given the blood and marrow were reinfused
i.v. The marrow was unfiltered apart from
its passage through the 300 ,um filter in a
standard blood-giving set. It wvas returned to
the, patient as fast as possible.
Management of patients after treatment.
Patients were barrier-nursed in single rooms
during the period of neutropenia, and non-
absorbed antibiotics were given orally to
suppress potential gutpathogens (Framycetiin,
colistin and nystatin- Storring d al., 1977).
Febrile episodes were treated promptly w!ith
broad-spectrum i.v. antibiotics, and platelet
concentrates wN-ere given when indicated.
RESULTS (11)
Complications of treatment
All patients were nauseated, and
vomited within 4 h of treatment, aind of
the anti-emetics used 5 mg haloperidol
i.v. appeared the most effective. Other-
wise there were no immediate complica-
tions, apart from the hypotensive episodes
mentioned above, and pain or discomfort
from the marrow aspiration sites were not
appreciable. After 5-6 days there was a
marked loss ofappetite, associated in most
cases with nausea and depression, which
persisted throughout the period of marrow
hypoplasia. Alopecia developed during the
3rd week. More serious complications
were febrile episodes, occurring in all
patients during the 2nd week and from 2
of whom organisms were isolated in blood
cultures (Staph. aureus and E. coli re-
spectively) and transient elevation of
blood urea in 2 patients (peak blood urea
levels 18 0 and 24 4 mM).
Fever resolved when the granulocyte
count rose above 400/mm3, so that the
ungrafted patients had longer periods of
pyrexia than the grafted ones.
Both patients whose blood urea levels
were raised after high-dose melphalan had
high urinary concentrations of the drug
during the first 2 h after its administra-
tion, and once the induction of a diuresis
with frusemide and i.v. saline became
routine practice there were no further
cases.
The effect of treatment upon the tumour
One patient (Case 8, Table I) achieved
complete remission. She had a large
axillary nodal recuirrence with extension
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into breast tissue and multiple liver
metastases. She remained in complete
remission for 4 months after treatment,
and then developed an axillary recurrence
which was treated with radiotherapy.
Seven months after treatment there was
still no evidence of recurrence of the liver
metastases. A second patient (Case 3) had
disease limited to the retroperitoneal
tissues and her abdominal ultrasonogram
cleared completely after high-dose melpha-
Ian, although minimal disease persisted
on lymphography. Of the remainder, 2
show-ed more than 500/ regression of
measurable skin deposits, as did a third
whose liver metastases progressed never-
theless. One patient had no response at all,
and the other 2 had transient regressions
of skin deposits. None of these partial
regressions was sustained for longer than
3 months.
The effect of treatment on blood count
The mean granulocyte and platelet
counts in the 8 grafted patients who re-
ceived 140 mg/M2 of melphalan are shown
in Fig. 5, and the actual granulocyte
C4-)
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7±13 on day 14
Fuzm. 5. Effect of marrow autotransplanta-
tion to 8 patients (- --) oIn platelet an(d
leucocyte recovery after i.v. melphalan
(140 mg/M2) compared with 4 patients
receiving lower (loses of melphalan (60-
125 mg/mr2) an(l no graft ( ). Bars
.shows 4-.s.d.
TABLE II. CGranidocyte
Patient
(mg/mi2 of
melphalan) 0
1. (60) 3000
2. (100) 4000
3. (100) 5100
4. (125) 12300
Mleani 6100
Patienit 0
1. 4600
2. 6500
3. 6700
4. 8000
5. 5000
6. 8360
7. 8000
8. 3000
Mtean 6260
counts and drug dosage in grafted and ungrafted patients after
i.v. melphalan on Day 0
Ungrafted patients
No. of days fiom melphalan injection
6
2000
800
3700
500(
290(0
10
400
0
0
300
175
16
30
7
()
7
22
60
'320
40
20(0
1.55
Grafte(d patients (all receiving 140 mg/m2 melphalan)
No. of (lays from melphalan injection
_ ..-A-
6
1700
350
1100
300
1400
700
950
940
930
10
300
60
150
150
400
200
1400
100
'345
14
90((
460
150
820
80
300
1200
100
500
16
1700
1050
200
2100
300
700
2500
1500
12,50
26
170
1000
560
570
575
32
400
3000
3200
:3000
2400
22
2000
2000
1530
1500
1200
1650
20
1(50
1000
950
1200
1(50
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counts and the dose of melphalan to each
patient are shown in Table II. These are
compared with those in the 4 patients
receiving melphalan alone in doses
ranging from 60 to 125 mg/M2 i.v. Note
that all the grafted patients received
higher doses of melphalan than the un-
grafted ones, and yet there was faster
recovery of the granulocyte count in the
grafted patients, an effect that can only
be due to the marrow graft.
After melphalan treatment in both
groups of patients, the total leucocyte
count remained normal for the first 5 days,
and then fell rapidly to a few hundred/
mm3. In both groups of patients the total
granulocyte counts had fallen to less than
500/mm3 by Day 10, with the exception of
one grafted patient in whom the lowest
recorded granulocyte count was 950/mm3
on Day 6. By Day 16, 3/4 of the non-
grafted patients had no detectable periph-
eral blood granulocytes, whereas of the
grafted patients 2 had counts ofmore than
2000/mm3, and 5 had counts of more than
1000/mm3. By Day 20 all the grafted
patients had granulocyte counts of 950/
mm3 or more. None of the non-grafted
patients had a count of more than 400 at
Day 22. The number of days taken to
establish a granulocyte count of 800/mm3
or greater was measured for each patient.
The 2 groups were significantly different
by the Mann-Whitney U test (P=0 01).
There was no significant acceleration of
platelet recovery in the grafted patients.
The reason for this is not known, but it is
well known that in patients receiving
marrow allografts from sibling donors a
similar tardiness in platelet recovery is
seen compared with the rate of granulo-
cyte recovery. Possibly it is more difficult
for megakaryocytic stem cells to become
established and to mature when trans-
planted. However, this is less of a prob-
lem, since supportive treatment with
platelet transfusions is readily available
and easily given.
DISCUSSION (II)
This study shows that autologous, un-
6
preserved marrow infused 8 h after high-
dose i.v. melphalan accelerates marrow
recovery, and this is reflected most
markedly in the recovery of peripheral-
blood granulocytes, where the time taken
for recovery to a mean count of 800/mm3
in the grafted patient was 7 days, com-
pared with 18 days in the non-grafted
ones.
The effect upon the tumours was dis-
appointing, apart from one patient in
whom there was a complete remission.
From this standpoint we have done little
to answer an outstanding question in
cancer chemotherapy-does increasing the
dose of drugs increase the response of
tumours? Experience with chemosensitive
transplanted animal tumours has shown
that this is so, but as Tattersall & Tobias
(1976) have pointed out, there is little
evidence in man that increasing the dose
of most c]inically useful antitumour drugs
does more than increase toxicity to the
patient. Clearly, in this context, the
choice ofboth tumour and drug is likely to
be important and, although we have found
that malignant melanoma is relatively
unresponsive to high-dose melphalan,
other tumours more sensitive to con-
ventional doses of alkylating agents, such
as ovarian cancer, lymphomas, neuro-
blastoms and breast cancer, may prove to
be more responsive.
The choice of drug for very-high-dose
chemotherapy is also bound to be limited
by the effect upon normal tissues other
than the marrow, even if means are avail-
able to protect or rescue the marrow from
drug damage. For example, it is un-
realistic to think of increasing the dose of
the many classes of drugs by more than
about twice the upper limit of conven-
tional dosage, since vinca alkaloids would
produce prohibitive neurotoxicity, anthra-
cycline antibiotics cardiotoxicity, nitroso-
ureas hepatoxicity and fluorouracil gastro-
intestinal toxicity. Even the well known
exception, methotrexate, which can be
given in enormous doses with folinic acid
rescue, has not been shown convincingly
to have an increased therapeutic effect
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when used in this way. In practice, we are
left with alkylating agents and even some
of these, such as cyclophosphamide and
ifosphamide, produce urothelial toxicity
which prohibits their use in very large
doses.
Finally, melphalan itself could not be
used in doses much greater than those
employed in this study since damage to
the gastrointestinal tract would super-
vene. Studies in sheep (Millar et al., 1978)
have shown that melphalan gut toxicity
can be reduced by the use of small
"priming" doses of cyclophosphamide
given before the melphalan, and we have
shown a similar sparing effect upon human
marrow (Hedley et al., 1978), but at pres-
ent there is no evidence that this effect
can be produced in human gut and, even
if it could, it is not known by how much
the melphalan dose could be increased nor
whether such an increase would be thera-
peutically valuable.
Our future policy will be cautiously to
explore the use of this treatment for
tumours known to be more sensitive than
malignant melanoma to alkylating agents
and in whom resistance to conventionally
employed agents has arisen.
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